Axsome Therapeutics Completes Successful FDA Pre-NDA Meeting for AXS-05 for the Treatment of Major Depressive Disorder
July 13, 2020 07:00 ET | Axsome Therapeutics, Inc.
 NDA submission on track for 4Q 2020 NEW YORK, July 13, 2020 (GLOBE NEWSWIRE) --  Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management...
Axsome Therapeutics Announces AXS-05 Achieves Primary Endpoint in GEMINI Phase 3 Trial in Major Depressive Disorder
December 16, 2019 06:00 ET | Axsome Therapeutics, Inc.
Demonstrated rapid, durable, and statistically significant improvement in depressive symptoms as measured by MADRS total score compared to placebo (p=0.002 on primary endpoint) Statistically...
Axsome Therapeutics Announces Completion of Patient Enrollment in the ASCEND Phase 2 Trial of AXS-05 in Major Depressive Disorder
November 14, 2018 07:00 ET | Axsome Therapeutics, Inc.
NEW YORK, Nov. 14, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...
Prestigious Aspen Institute Ascend Fellowship Announces 2018 Class of Leaders
September 06, 2018 12:00 ET | The Aspen Institute
Washington, DC, Sept. 06, 2018 (GLOBE NEWSWIRE) -- The Aspen Institute announced today the 2018 class of Aspen Institute Ascend Fellows. The Ascend Fellowship invests in diverse, entrepreneurial...
AWeber Logo
All-Star Speaker Lineup Announced for ASCEND Digital Marketing Summit 2015
March 26, 2015 08:11 ET | AWeber Communications
CHALFONT, Pa., March 26, 2015 (GLOBE NEWSWIRE) -- Email marketing powerhouse, AWeber, is pleased to present its annual Digital Marketing Summit, ASCEND, on October 18th through October 20th at The...